journal article·2025-08Open access

Real‐Time Evolutionary Landscape of the Bronchial Epithelium and Corresponding Dynamic Immune Cell Alterations in Lung Squamous Cell Carcinogenesis

Baohong Luo, Yuting Luo, Sicheng Chen, Tiantian Yang, Bixia Liu, Xiting Liao, Xiaoke Zheng, Tian Tian, Jinxu Liu, Qinru Zhan, Xiaohua Situ, Zhongpeng Xie, Yanxia Wang, Zhe‐Sheng Chen, Honglei Chen, Zheng Yang, Zunfu Ke

Advanced Science· Volume 12· Issue 31

Abstract

Abstract The molecular mechanism by which tumor cells and their microenvironment evolve during lung squamous cell carcinoma (LUSC) carcinogenesis remains unclear, greatly limiting its early diagnosis and treatment effectiveness in patients. To replicate pathogenic processes and identify the determinants of cell evolution, a rat model is established using tobacco‐derived carcinogens. Here, a series of single‐cell transcriptome profiles of normal lung epithelium, hyperplasia, metaplasia, dysplasia, and squamous cell carcinoma in situ (CIS) to invasive squamous cell carcinoma (SCC) is presented. A large proportion of canonical copy number variations (CNVs) are detected in the hyperplasia/metaplasia stages, with their frequency increasing as the lesion progressed. Although bronchial epithelial cells exhibit substantial heterogeneity, three distinct cellular states are identified during their evolution into malignant cells. Immune sensing occurs at the earliest stages of cellular transformation. However, persistent exposure to carcinogens induces microenvironmental remodeling, which is characterized by monocyte‐derived macrophage infiltration, plasmacytoid dendritic cell expansion, and progressive T‐cell exhaustion. These findings depict the evolutionary trajectory of cancer and the immune microenvironment, emphasizing the need for CNV evaluation in early screening and immune‐based therapy for lesions at a high risk of progression to LUSC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Single-cell and spatial transcriptomics · Cancer Genomics and Diagnostics · Epigenetics and DNA Methylation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pathology The First Affiliated Hospital Sun Yat‐sen University Guangzhou Guangdong 510000 P. R. China

Molecular Diagnosis and Gene Test Center The First Affiliated Hospital Sun Yat‐Sen University Guangzhou Guangdong 510000 P. R. China

Department of Pathology The Seventh Affiliated Hospital Sun Yat‐sen University Shenzhen Guangdong 518000 P. R. China

Department of Pharmaceutical Sciences College of Pharmacy and Health Sciences St. John's University Queens, New York 11439 USA

Department of Pathology Zhongnan Hospital Wuhan University Wuhan Hubei 430000 P. R. China

Funding

National Natural Science Foundation of China · Guangdong Provincial Department of Science and Technology

References (74)

Show source-provided references
1. Derman B. A. · Translat. Lung Cancer Res. · 2015 · 4 · 524
2. 10.1093/annonc/mdw43710.1093/annonc/mdw437 ↗
3. Paik P. K. · Ann. Meet. · 2019 · 39
4. 10.1016/S0140-6736(16)32517-X10.1016/S0140-6736(16)32517-X ↗
5. 10.1200/JCO.2017.74.306210.1200/JCO.2017.74.3062 ↗
6. 10.1097/JTO.000000000000063010.1097/JTO.0000000000000630 ↗
7. 10.1016/j.ctrv.2017.05.00910.1016/j.ctrv.2017.05.009 ↗
8. 10.1158/1940-6207.CAPR-15-040010.1158/1940-6207.CAPR-15-0400 ↗
9. 10.1158/1940-6207.CAPR-15-030510.1158/1940-6207.CAPR-15-0305 ↗
10. 10.1164/rccm.201504-0822OC10.1164/rccm.201504-0822OC ↗
11. 10.1038/s41467-019-09834-210.1038/s41467-019-09834-2 ↗
12. 10.1038/s41586-019-1330-010.1038/s41586-019-1330-0 ↗
13. 10.1158/0008-5472.CAN-17-382210.1158/0008-5472.CAN-17-3822 ↗
14. 10.1038/s41591-018-0323-010.1038/s41591-018-0323-0 ↗
15. 10.1038/s41388-021-01723-710.1038/s41388-021-01723-7 ↗
16. 10.1016/j.scitotenv.2020.14483910.1016/j.scitotenv.2020.144839 ↗
17. 10.1016/j.fct.2018.11.01410.1016/j.fct.2018.11.014 ↗
18. 10.1038/srep2729510.1038/srep27295 ↗
19. 10.1073/pnas.220382812010.1073/pnas.2203828120 ↗
20. 10.1126/science.125425710.1126/science.1254257 ↗
21. 10.1038/s41467-019-14256-110.1038/s41467-019-14256-1 ↗
22. 10.1038/s41467-020-20059-610.1038/s41467-020-20059-6 ↗
23. 10.1038/nmeth.446310.1038/nmeth.4463 ↗
24. 10.1038/nmeth.440210.1038/nmeth.4402 ↗
25. 10.1038/s41577-021-00574-310.1038/s41577-021-00574-3 ↗
26. Cai L. · J. Hematol. Oncol. · 2023 · 16
27. 10.1038/s41568-022-00546-210.1038/s41568-022-00546-2 ↗
28. 10.1016/j.immuni.2022.01.01610.1016/j.immuni.2022.01.016 ↗
29. Han W. · Front. Oncol. · 2024 · 14
30. 10.1158/1078-0432.CCR-16-254010.1158/1078-0432.CCR-16-2540 ↗
31. 10.1073/pnas.201928211810.1073/pnas.2019282118 ↗
32. 10.1016/j.critrevonc.2013.06.01110.1016/j.critrevonc.2013.06.011 ↗
33. 10.1002/ijc.3329210.1002/ijc.33292 ↗
34. 10.1002/mc.2260110.1002/mc.22601 ↗
35. 10.1371/journal.pone.020028510.1371/journal.pone.0200285 ↗
36. 10.1186/s12885-018-4068-410.1186/s12885-018-4068-4 ↗
37. 10.1539/joh.17-0102-RA10.1539/joh.17-0102-RA ↗
38. 10.3390/ph1602022110.3390/ph16020221 ↗
39. Mohamed E. E. · Apoptosis, Cell Proliferat., Cancers · 2023 · 15
40. 10.1016/j.canlet.2005.02.02410.1016/j.canlet.2005.02.024 ↗
41. 10.7150/ijms.6780610.7150/ijms.67806 ↗
42. 10.1016/j.lungcan.2019.07.00110.1016/j.lungcan.2019.07.001 ↗
43. 10.1016/j.toxlet.2009.04.02210.1016/j.toxlet.2009.04.022 ↗
44. 10.1056/NEJM19610810265060110.1056/NEJM196108102650601 ↗
45. 10.1158/2159-8290.CD-19-136610.1158/2159-8290.CD-19-1366 ↗
46. 10.1016/j.jtho.2023.09.27510.1016/j.jtho.2023.09.275 ↗
47. 10.1101/gr.175141.11410.1101/gr.175141.114 ↗
48. 10.1038/s41392-022-01200-x10.1038/s41392-022-01200-x ↗
49. 10.1002/hep.2413310.1002/hep.24133 ↗
50. 10.1080/15384101.2021.202004110.1080/15384101.2021.2020041 ↗
51. 10.15252/emmm.20231776110.15252/emmm.202317761 ↗
52. 10.1007/s12038-020-9999-710.1007/s12038-020-9999-7 ↗
53. 10.1097/PAT.0b013e32835f45fd10.1097/PAT.0b013e32835f45fd ↗
54. Roberts M. · eLife · 2023 · 12
55. 10.1007/s00403-013-1415-910.1007/s00403-013-1415-9 ↗
56. Jia Y. · Front. Oncol. · 2023 · 13
57. Ogunnigbagbe O. · Biochim. Biophys. Acta (BBA) – Rev. Cancer · 2022 · 1877
58. 10.1183/16000617.0122-202110.1183/16000617.0122-2021 ↗
59. 10.1016/j.jtho.2017.11.13210.1016/j.jtho.2017.11.132 ↗
60. Kuah C. Y. · Therapeutic Adv. Med. Oncol. · 2023 · 15
61. 10.1001/jamanetworkopen.2024.128510.1001/jamanetworkopen.2024.1285 ↗
62. 10.21147/j.issn.1000-9604.2022.06.0110.21147/j.issn.1000-9604.2022.06.01 ↗
63. 10.1016/j.ccell.2023.02.00910.1016/j.ccell.2023.02.009 ↗
64. 10.1016/j.cell.2017.04.01410.1016/j.cell.2017.04.014 ↗
65. 10.1038/s41586-021-03651-810.1038/s41586-021-03651-8 ↗
66. 10.1016/j.ccell.2021.10.00910.1016/j.ccell.2021.10.009 ↗
67. 10.1038/s41590-023-01475-410.1038/s41590-023-01475-4 ↗
68. 10.1016/j.cell.2020.06.03210.1016/j.cell.2020.06.032 ↗
69. 10.1016/j.cell.2020.07.01310.1016/j.cell.2020.07.013 ↗
70. 10.1016/j.celrep.2021.10984410.1016/j.celrep.2021.109844 ↗
71. 10.1016/j.oraloncology.2019.07.01910.1016/j.oraloncology.2019.07.019 ↗
72. Wu J. · Front. Immunol. · 2021 · 12
73. 10.1158/0008-5472.CAN-22-119910.1158/0008-5472.CAN-22-1199 ↗
74. 10.1016/j.jneuroim.2018.06.01210.1016/j.jneuroim.2018.06.012 ↗